Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Digestive Diseases and Sciences
Erschienen in: Digestive Diseases and Sciences 1/2022

19.01.2021 | Review

Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, “Prediabetes,” Diabetes and Atherosclerosis

verfasst von: T. D. Filippatos, K. Alexakis, V. Mavrikaki, D. P. Mikhailidis

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Fat accumulation in the pancreas associated with obesity and the metabolic syndrome (MetS) has been defined as “non-alcoholic fatty pancreas disease” (NAFPD). The aim of this review is to describe the association of NAFPD with obesity, MetS, type 2 diabetes mellitus (T2DM) and atherosclerosis and also increase awareness regarding NAFPD. Various methods are used for the detection and quantification of pancreatic fat accumulation that may play a significant role in the differences that have been observed in the prevalence of NAFPD. Endoscopic ultrasound provides detailed images of the pancreas and its use is expected to increase in the future. Obesity and MetS have been recognized as NAFPD risk factors. NAFPD is strongly associated with non-alcoholic fatty liver disease (NAFLD) and it seems that the presence of both may be related with aggravation of NAFLD. A role of NAFPD in the development of “prediabetes” and T2DM has also been suggested by most human studies. Accumulation of fat in pancreatic tissue possibly initiates a vicious cycle of beta-cell deterioration and further pancreatic fat accumulation. Additionally, some evidence indicates a correlation between NAFPD and atherosclerotic markers (e.g., carotid intima–media thickness). Weight loss and bariatric surgery decreases pancreatic triglyceride content but pharmacologic treatments for NAFPD have not been evaluated in specifically designed studies. Hence, NAFPD is a marker of local fat accumulation possibly associated with beta-cell function impairment, carbohydrate metabolism disorders and atherosclerosis.
Literatur
1.
Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of obesity among adults and youth: United States, 2011–2014. NCHS Data Brief 2015;219:1–8
2.
Neeland IJ, Ross R, Després J-P, Matsuzawa Y, Yamashita S, Shai I et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol 2019;7:715–725PubMed
3.
Katsiki N, Athyros VG, Mikhailidis DP. Abnormal peri-organ or intra-organ fat (APIFat) deposition: an underestimated predictor of vascular risk? Curr Vasc Pharmacol 2016;14:432–441PubMed
4.
Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014;2:901–910PubMed
5.
Smits MM, van Geenen EJM. The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol 2011;8:169–177PubMed
6.
Majumder S, Philip NA, Takahashi N, Levy MJ, Singh VP, Chari ST. Fatty pancreas: Should we be concerned? Pancreas 2017;46:1251–1258PubMedPubMedCentral
7.
Tariq H, Nayudu S, Akella S, Glandt M, Chilimuri S. Non-alcoholic fatty pancreatic disease: a review of literature. Gastroenterol Res 2016;9:87–91
8.
Pinte L, Balaban DV, Băicuş C, Jinga M. Non-alcoholic fatty pancreas disease—practices for clinicians. Romanian J Intern Med Rev Roum Med Interne 2019;57:209–219
9.
Alempijevic T, Dragasevic S, Zec S, Popovic D, Milosavljevic T. Non-alcoholic fatty pancreas disease. Postgrad Med J 2017;93:226–230PubMed
10.
Shah N, Rocha JP, Bhutiani N, Endashaw O. Nonalcoholic fatty pancreas disease. Nutr Clin Pract 2019;34:S49-56PubMed
11.
Romana BS, Chela H, Dailey FE, Nassir F, Tahan V. Non-alcoholic fatty pancreas disease (NAFPD): a silent spectator or the fifth component of metabolic syndrome? A literature review. Endocr Metab Immune Disord Drug Targets 2018;18:547–554PubMed
12.
Zhou J, Li M-L, Zhang D-D, Lin H-Y, Dai X-H, Sun X-L et al. The correlation between pancreatic steatosis and metabolic syndrome in a Chinese population. Pancreatol Off J Int Assoc Pancreatol IAP Al 2016;16:578–583
13.
Lesmana CRA, Pakasi LS, Inggriani S, Aidawati ML, Lesmana LA. Prevalence of Non-Alcoholic Fatty Pancreas Disease (NAFPD) and its risk factors among adult medical check-up patients in a private hospital: a large cross sectional study. BMC Gastroenterol 2015;15:174PubMedPubMedCentral
14.
Wang C-Y, Ou H-Y, Chen M-F, Chang T-C, Chang C-J. Enigmatic ectopic fat: prevalence of nonalcoholic fatty pancreas disease and its associated factors in a Chinese population. J Am Heart Assoc 2014;3:e000297PubMedPubMedCentral
15.
Pham YH, Bingham BA, Bell CS, Greenfield SA, John SD, Robinson LH et al. Prevalence of pancreatic steatosis at a pediatric tertiary care center. South Med J 2016;109:196–198PubMed
16.
Saisho Y, Butler AE, Meier JJ, Monchamp T, Allen-Auerbach M, Rizza RA et al. Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. Clin Anat N Y N 2007;20:933–942
17.
Li J, Xie Y, Yuan F, Song B, Tang C. Noninvasive quantification of pancreatic fat in healthy male population using chemical shift magnetic resonance imaging: effect of aging on pancreatic fat content. Pancreas 2011;40:295–299PubMed
18.
Singh RG, Yoon HD, Wu LM, Lu J, Plank LD, Petrov MS. Ectopic fat accumulation in the pancreas and its clinical relevance: A systematic review, meta-analysis, and meta-regression. Metabolism 2017;69:1–13PubMed
19.
Coe PO, Williams SR, Morris DM, Parkin E, Harvie M, Renehan AG et al. Development of MR quantified pancreatic fat deposition as a cancer risk biomarker. Pancreatol Off J Int Assoc Pancreatol IAP Al 2018;18:429–437
20.
21.
Yuan F, Song B, Huang Z, Xia C, Liu X. Quantification of pancreatic fat with dual-echo imaging at 3.0-T MR in clinical application: how do the corrections for T1 and T2* relaxation effect work and simplified correction strategy. Acta Radiol 2018;59:1021–1028PubMed
22.
Kato S, Iwasaki A, Kurita Y, Arimoto J, Yamamoto T, Hasegawa S et al. Three-dimensional analysis of pancreatic fat by fat-water magnetic resonance imaging provides detailed characterization of pancreatic steatosis with improved reproducibility. PLoS ONE 2019;14:e0224921PubMedPubMedCentral
23.
Gaborit B, Abdesselam I, Kober F, Jacquier A, Ronsin O, Emungania O et al. Ectopic fat storage in the pancreas using 1H-MRS: importance of diabetic status and modulation with bariatric surgery-induced weight loss. Int J Obest 2015;39:480–487
24.
Marks WM, Filly RA, Callen PW. Ultrasonic evaluation of normal pancreatic echogenicity and its relationship to fat deposition. Radiology 1980;137:475–479PubMed
25.
Sakai NS, Taylor SA, Chouhan MD. Obesity, metabolic disease and the pancreas-quantitative imaging of pancreatic fat. Br J Radiol 2018;91:20180267PubMedPubMedCentral
26.
Kim SY, Kim H, Cho JY, Lim S, Cha K, Lee KH et al. Quantitative assessment of pancreatic fat by using unenhanced CT: pathologic correlation and clinical implications. Radiology 2014;271:104–112PubMed
27.
Balthazar EJ. CT contrast enhancement of the pancreas: patterns of enhancement, pitfalls and clinical implications. Pancreatol Off J Int Assoc Pancreatol IAP Al 2011;11:585–587
28.
Idilman IS, Aniktar H, Idilman R, Kabacam G, Savas B, Elhan A et al. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology 2013;267:767–775PubMed
29.
Idilman IS, Tuzun A, Savas B, Elhan AH, Celik A, Idilman R et al. Quantification of liver, pancreas, kidney, and vertebral body MRI-PDFF in non-alcoholic fatty liver disease. Abdom Imaging 2015;40:1512–1519PubMed
30.
Hu HH, Kim H-W, Nayak KS, Goran MI. Comparison of fat-water MRI and single-voxel MRS in the assessment of hepatic and pancreatic fat fractions in humans. Obes Silver Spring Md 2010;18:841–847
31.
Kühn J-P, Berthold F, Mayerle J, Völzke H, Reeder SB, Rathmann W et al. Pancreatic steatosis demonstrated at MR imaging in the general population: clinical relevance. Radiology 2015;276:129** – 136PubMed
32.
Al-Haddad M, Khashab M, Zyromski N, Pungpapong S, Wallace MB, Scolapio J et al. Risk factors for hyperechogenic pancreas on endoscopic ultrasound: a case-control study. Pancreas 2009;38:672–675PubMed
33.
Sepe PS, Ohri A, Sanaka S, Berzin TM, Sekhon S, Bennett G et al. A prospective evaluation of fatty pancreas by using EUS. Gastrointest Endosc 2011;73:987–993PubMed
34.
Katsiki N, Perez-Martinez P, Anagnostis P, Mikhailidis DP, Karagiannis A. Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome? Curr Vasc Pharmacol 2018;16:219–227PubMed
35.
Mullish BH, Forlano R, Manousou P, Mikhailidis DP. Non-alcoholic fatty liver disease and cardiovascular risk: an update. Expert Rev Gastroenterol Hepatol 2018;12:1175–1177PubMed
36.
Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017;71:17–32PubMed
37.
Sijens PE, Edens MA, Bakker SJL, Stolk RP. MRI-determined fat content of human liver, pancreas and kidney. World J Gastroenterol 2010;16:1993–1998PubMedPubMedCentral
38.
Patel NS, Peterson MR, Brenner DA, Heba E, Sirlin C, Loomba R. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013;37:630–639PubMedPubMedCentral
39.
Lee JS, Kim SH, Jun DW, Han JH, Jang EC, Park JY et al. Clinical implications of fatty pancreas: correlations between fatty pancreas and metabolic syndrome. World J Gastroenterol 2009;15:1869–1875PubMedPubMedCentral
40.
Wang D, Yu X-P, Xiao W-M, Jiao X-P, Wu J, Teng D-L et al. Prevalence and clinical characteristics of fatty pancreas in Yangzhou, China: A cross-sectional study. Pancreatol Off J Int Assoc Pancreatol IAP Al 2018;18:263–268
41.
Li S, Su L, Lv G, Zhao W, Chen J. Transabdominal ultrasonography of the pancreas is superior to that of the liver for detection of ectopic fat deposits resulting from metabolic syndrome. Medicine (Baltimore) 2017;96:e8060
42.
van Geenen E-JM, Smits MM, Schreuder TCMA, van der Peet DL, Bloemena E, Mulder CJJ. Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. Pancreas 2010;39:1185–1190PubMed
43.
44.
Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S et al. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ 2016;353:i2156PubMedPubMedCentral
45.
Ryan DH, Kahan S. Guideline recommendations for obesity management. Med Clin North Am 2018;102:49–63PubMed
46.
Filippatos TD, Kyrou I, Georgousopoulou EN, Chrysohoou C, Kouli G-M, Tsigos C et al. Modeling anthropometric indices in relation to 10-year (2002–2012) incidence of cardiovascular disease, among apparently healthy individuals: the ATTICA study. Diabetes Metab Syndr 2017;11:S789–S795PubMed
47.
Kotsis V, Tsioufis K, Antza C, Seravalle G, Coca A, Sierra C et al. Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directions. J Hypertens 2018;36:1441–1455PubMed
48.
Kotsis V, Jordan J, Micic D, Finer N, Leitner DR, Toplak H et al. Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment. J Hypertens 2018;36:1427–1440PubMed
49.
Katsiki N, Anagnostis P, Kotsa K, Goulis DG, Mikhailidis DP. Obesity, metabolic syndrome and the risk of microvascular complications in patients with diabetes mellitus. Curr Pharm Des 2019;25:2051–2059PubMed
50.
Katsiki N, Mikhailidis DP, Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacol Sin 2018;39:1176–1188PubMedPubMedCentral
51.
Katsiki N, Mantzoros C, Mikhailidis DP. Adiponectin, lipids and atherosclerosis. Curr Opin Lipidol 2017;28:347–354PubMed
52.
Filippatos TD, Liberopoulos E, Georgoula M, Tellis CC, Tselepis AD, Elisaf M. Effects of increased body weight and short-term weight loss on serum PCSK9 levels—a prospective pilot study. Arch Med Sci Atheroscler Dis 2017;2:e46-51PubMedPubMedCentral
53.
Seifalian AM, Filippatos TD, Joshi J, Mikhailidis DP. Obesity and arterial compliance alterations. Curr Vasc Pharmacol 2010;8:155–168PubMed
54.
Milionis HJ, Filippatos TD, Derdemezis CS, Kalantzi KJ, Goudevenos J, Seferiadis K et al. Excess body weight and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. Eur J Neurol 2007;14:762–769PubMed
55.
Pienkowska J, Brzeska B, Kaszubowski M, Kozak O, Jankowska A, Szurowska E. MRI assessment of ectopic fat accumulation in pancreas, liver and skeletal muscle in patients with obesity, overweight and normal BMI in correlation with the presence of central obesity and metabolic syndrome. Diabetes Metab Syndr Obes 2019;12:623–636PubMedPubMedCentral
56.
Le KA, Ventura EE, Fisher JQ, Davis JN, Weigensberg MJ, Punyanitya M et al. Ethnic differences in pancreatic fat accumulation and its relationship with other fat depots and inflammatory markers. Diabetes Care 2011;34:485–490PubMedPubMedCentral
57.
Choi CW, Kim GH, Kang DH, Kim HW, Kim DU, Heo J et al. Associated factors for a hyperechogenic pancreas on endoscopic ultrasound. World J Gastroenterol 2010;16:4329–4334PubMedPubMedCentral
58.
Rossi AP, Fantin F, Zamboni GA, Mazzali G, Rinaldi CA, Del Giglio M et al. Predictors of ectopic fat accumulation in liver and pancreas in obese men and women. Obes Silver Spring 2011;19:1747–1754
59.
Targher G, Rossi AP, Zamboni GA, Fantin F, Antonioli A, Corzato F et al. Pancreatic fat accumulation and its relationship with liver fat content and other fat depots in obese individuals. J Endocrinol Investig 2012;35:748–753
60.
Makino N, Shirahata N, Honda T, Ando Y, Matsuda A, Ikeda Y et al. Pancreatic hyperechogenicity associated with hypoadiponectinemia and insulin resistance: a Japanese population study. World J Hepatol 2016;8:1452–1458PubMedPubMedCentral
61.
Moschen AR, Adolph TE, Gerner RR, Wieser V, Tilg H. Lipocalin-2: a master mediator of intestinal and metabolic inflammation. Trends Endocrinol Metab 2017;28:388–397PubMed
62.
Singh RG, Nguyen NN, Cervantes A, Kim JU, Stuart CE, Petrov MS. Circulating levels of lipocalin-2 are associated with fatty pancreas but not fatty liver. Peptides 2019;119:170117PubMed
63.
Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update. World J Gastroenterol 2015;21:6820–6834PubMedPubMedCentral
64.
Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism 2016;65:1109–1123PubMed
65.
Nunez-Duran E, Chanclon B, Sutt S, Real J, Marschall HU, Wernstedt Asterholm I et al. Protein kinase STK25 aggravates the severity of non-alcoholic fatty pancreas disease in mice. J Endocrinol 2017;234:15–27PubMedPubMedCentral
66.
Heni M, Machann J, Staiger H, Schwenzer NF, Peter A, Schick F et al. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study. Diabetes Metab Res Rev 2010;26:200–205PubMed
67.
Schwenzer NF, Machann J, Martirosian P, Stefan N, Schraml C, Fritsche A et al. Quantification of pancreatic lipomatosis and liver steatosis by MRI: comparison of in/opposed-phase and spectral-spatial excitation techniques. Investig Radiol 2008;43:330–337
68.
Pinnick KE, Collins SC, Londos C, Gauguier D, Clark A, Fielding BA. Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition. Obes Silver Spring 2008;16:522–530
69.
Szczepaniak LS, Victor RG, Mathur R, Nelson MD, Szczepaniak EW, Tyer N et al. Pancreatic steatosis and its relationship to beta-cell dysfunction in humans: racial and ethnic variations. Diabetes Care 2012;35:2377–2383PubMedPubMedCentral
70.
Soeda J, Mouralidarane A, Cordero P, Li J, Nguyen V, Carter R et al. Maternal obesity alters endoplasmic reticulum homeostasis in offspring pancreas. J Physiol Biochem 2016;72:281–291PubMedPubMedCentral
71.
Carter R, Mouralidarane A, Soeda J, Ray S, Pombo J, Saraswati R et al. Non-alcoholic fatty pancreas disease pathogenesis: a role for developmental programming and altered circadian rhythms. PLoS ONE 2014;9:e89505PubMedPubMedCentral
72.
Oben JA, Patel T, Mouralidarane A, Samuelsson AM, Matthews P, Pombo J et al. Maternal obesity programmes offspring development of non-alcoholic fatty pancreas disease. Biochem Biophys Res Commun 2010;394:24–28PubMedPubMedCentral
73.
Gazi I, Tsimihodimos V, Filippatos T, Bairaktari E, Tselepis AD, Elisaf M. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism 2006;55:885–891PubMed
74.
Lagos KG, Filippatos TD, Tsimihodimos V, Gazi IF, Rizos C, Tselepis AD et al. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids 2009;44:9–16PubMed
75.
Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. Curr Vasc Pharmacol 2014;12:627–641PubMed
76.
Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, Rizzo M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients 2013;5:928–948PubMedPubMedCentral
77.
Kostapanos MS, Florentin M, Elisaf MS, Mikhailidis DP. Hemostatic factors and the metabolic syndrome. Curr Vasc Pharmacol 2013;11:880–905PubMed
78.
Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Banach M. Metabolic syndrome and renal disease. Int J Cardiol 2013;164:141–150PubMed
79.
Anagnostis P, Katsiki N, Adamidou F, Athyros VG, Karagiannis A, Kita M et al. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Metabolism 2013;62:21–33PubMed
80.
Perez-Martinez P, Mikhailidis DP, Athyros VG, Bullo M, Couture P, Covas MI et al. Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. Nutr Rev 2017;75:307–326PubMedPubMedCentral
81.
Laou E, Milionis H, Petrou A, Arnaoutoglou E, Glantzounis G, Bairaktari E et al. The impact of metabolic syndrome and its components on perioperative outcomes after elective laparotomy—a prospective observational study. Am J Surg 2017;214:831–837PubMed
82.
Athyros VG, Mikhailidis DP. High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes, Implications for everyday practice. J Diabetes Complicat 2016;30:9–11
83.
Tzimas P, Petrou A, Laou E, Milionis H, Mikhailidis DP, Papadopoulos G. Impact of metabolic syndrome in surgical patients: should we bother? Br J Anaesth 2015;115:194–202PubMed
84.
Katsiki N, Athyros VG, Mikhailidis DP. Metabolic syndrome: Different definitions and gender-specific associations with cardiovascular risk factors. Diab Vasc Res 2015;12:471–472
85.
Catanzaro R, Cuffari B, Italia A, Marotta F. Exploring the metabolic syndrome: nonalcoholic fatty pancreas disease. World J Gastroenterol 2016;22:7660–7675PubMedPubMedCentral
86.
Bi Y, Wang JL, Li ML, Zhou J, Sun XL. The association between pancreas steatosis and metabolic syndrome: a systematic review and meta-analysis. Diabetes Metab Res Rev 2019;35:e3142PubMed
87.
88.
89.
Weng S, Zhou J, Chen X, Sun Y, Mao Z, Chai K. Prevalence and factors associated with nonalcoholic fatty pancreas disease and its severity in China. Medicine (Baltimore) 2018;97:e11293
90.
Cohen M, Syme C, Deforest M, Wells G, Detzler G, Cheng HL et al. Ectopic fat in youth: the contribution of hepatic and pancreatic fat to metabolic disturbances. Obes Silver Spring 2014;22:1280–1286
91.
Maggio AB, Mueller P, Wacker J, Viallon M, Belli DC, Beghetti M et al. Increased pancreatic fat fraction is present in obese adolescents with metabolic syndrome. J Pediatr Gastroenterol Nutr 2012;54:720–726PubMed
92.
Staaf J, Labmayr V, Paulmichl K, Manell H, Cen J, Ciba I et al. Pancreatic fat is associated with metabolic syndrome and visceral fat but not beta-cell function or body mass index in pediatric obesity. Pancreas 2017;46:358–365PubMed
93.
Elhady M, Elazab A, Bahagat KA, Abdallah NA, Ibrahim GE. Fatty pancreas in relation to insulin resistance and metabolic syndrome in children with obesity. J Pediatr Endocrinol Metab 2019;32:19–26PubMed
94.
Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 2016;355:i5953PubMedPubMedCentral
95.
Filippatos TD, Panagiotakos DB, Georgousopoulou EN, Pitaraki E, Kouli GM, Chrysohoou C et al. Mediterranean diet and 10-year (2002–2012) incidence of diabetes and cardiovascular disease in participants with prediabetes: the ATTICA study. Rev Diabet Stud 2016;13:226–235PubMed
96.
Filippatos TD, Rizos EC, Gazi IF, Lagos K, Agouridis D, Mikhailidis DP et al. Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study. Arch Med Sci 2013;9:788–795PubMedPubMedCentral
97.
Filippatos TD, Rizos EC, Tsimihodimos V, Gazi IF, Tselepis AD, Elisaf MS. Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A(2) in subjects with prediabetes. Lipids 2013;48:547–555PubMed
98.
Nowotny B, Kahl S, Kluppelholz B, Hoffmann B, Giani G, Livingstone R et al. Circulating triacylglycerols but not pancreatic fat associate with insulin secretion in healthy humans. Metabolism 2018;81:113–125PubMed
99.
Hung CS, Tseng PH, Tu CH, Chen CC, Liao WC, Lee YC et al. Increased pancreatic echogenicity with US: relationship to glycemic progression and incident diabetes. Radiology 2018;287:853–863PubMed
100.
Fatima J, Gupta N, Karoli R, Chandra A, Jagirdaar S, Arora R et al. Association of sonographically assessed visceral and subcutaneous abdominal fat with insulin resistance in prediabetes. J Assoc Physicians India 2019;67:68–70PubMed
101.
Uygun A, Kadayifci A, Demirci H, Saglam M, Sakin YS, Ozturk K et al. The effect of fatty pancreas on serum glucose parameters in patients with nonalcoholic steatohepatitis. Eur J Intern Med 2015;26:37–41PubMed
102.
Pacifico L, Di Martino M, Anania C, Andreoli GM, Bezzi M, Catalano C et al. Pancreatic fat and beta-cell function in overweight/obese children with nonalcoholic fatty liver disease. World J Gastroenterol 2015;21:4688–4695PubMedPubMedCentral
103.
Zhao ZZ, Xin LL, Xia JH, Yang SL, Chen YX, Li K. Long-term high-fat high-sucrose diet promotes enlarged islets and beta-cell damage by oxidative stress in bama minipigs. Pancreas 2015;44:888–895PubMed
104.
van Raalte DH, van der Zijl NJ, Diamant M. Pancreatic steatosis in humans: cause or marker of lipotoxicity? Curr Opin Clin Nutr Metab Care 2010;13:478–485PubMed
105.
Miyake H, Sakagami J, Yasuda H, Sogame Y, Kato R, Suwa K et al. Association of fatty pancreas with pancreatic endocrine and exocrine function. PLoS ONE 2018;13:e0209448PubMedPubMedCentral
106.
van der Zijl NJ, Goossens GH, Moors CC, van Raalte DH, Muskiet MH, Pouwels PJ et al. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on beta-cell function in individuals with impaired glucose metabolism. J Clin Endocrinol Metab 2011;96:459–467PubMed
107.
Ozturk K, Dogan T, Celikkanat S, Ozen A, Demirci H, Kurt O et al. The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2018;30:411–417PubMed
108.
Gerst F, Wagner R, Kaiser G, Panse M, Heni M, Machann J et al. Metabolic crosstalk between fatty pancreas and fatty liver: effects on local inflammation and insulin secretion. Diabetologia 2017;60:2240–2251PubMed
109.
110.
Quiclet C, Dittberner N, Gassler A, Stadion M, Gerst F, Helms A et al. Pancreatic adipocytes mediate hypersecretion of insulin in diabetes-susceptible mice. Metabolism 2019;97:9–17PubMed
111.
Katsiki N, Dimitriadis G, Mikhailidis DP. Perirenal adiposity and other excessive intra- and peri-organ fat depots: what is the connection? Angiology 2019;70:581–583PubMed
112.
Katsiki N, Mikhailidis DP. Abnormal peri-organ or intra-organ fat deposition and vascular risk. Angiology 2018;69:841–842PubMed
113.
Gerst F, Wagner R, Oquendo MB, Siegel-Axel D, Fritsche A, Heni M et al. What role do fat cells play in pancreatic tissue? Mol Metab 2019;25:1–10PubMedPubMedCentral
114.
Yamazaki H, Tauchi S, Kimachi M, Dohke M, Hanawa N, Kodama Y et al. Independent association between prediabetes and future pancreatic fat accumulation: a 5-year Japanese cohort study. J Gastroenterol 2018;53:873–882PubMed
115.
Wang LCC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: Cardiovascular disease in diabetes mellitus: Atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus—mechanisms, management, and clinical considerations. Circulation 2016;133:2459–2502
116.
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2018;14:88–98PubMed
117.
Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol 2018;17:83PubMedPubMedCentral
118.
Wang H, Ba Y, Cai RC, Xing Q. Association between diabetes mellitus and the risk for major cardiovascular outcomes and all-cause mortality in women compared with men: a meta-analysis of prospective cohort studies. BMJ Open 2019;9:e024935PubMedPubMedCentral
119.
Filippatos T, Tsimihodimos V, Pappa E, Elisaf M. Pathophysiology of diabetic dyslipidaemia. Curr Vasc Pharmacol 2017;15:566–575PubMed
120.
Filippatos TD, Florentin M, Georgoula M, Elisaf MS. Pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol 2017;10:187–200PubMed
121.
Agouridis AP, Rizos CV, Elisaf MS, Filippatos TD. Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia? Rev Diabet Stud 2013;10:171–190PubMedPubMedCentral
122.
Katsiki N, Kotsa K, Athyros VG, Mikhailidis DP. Statin use in patients with diabetes: one drug, multiple benefits. Expert Rev Cardiovasc Ther 2019;17:1–2
123.
Katsiki N, Purrello F, Tsioufis C, Mikhailidis DP. Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opin Pharmacother 2017;18:1243–1260PubMed
124.
Zsori G, Illes D, Ivany E, Kosar K, Holzinger G, Tajti M et al. In new-onset diabetes mellitus, metformin reduces fat accumulation in the liver, but not in the pancreas or pericardium. Metab Syndr Relat Disord 2019;17:289–295PubMed
125.
Dite P, Blaho M, Bojkova M, Jabandziev P, Kunovsky L. Nonalcoholic fatty pancreas disease: clinical consequences. Dig Dis Basel Switz 2020;38:143–149
126.
Ou HY, Wang CY, Yang YC, Chen MF, Chang CJ. The association between nonalcoholic fatty pancreas disease and diabetes. PLoS ONE 2013;8:e62561PubMedPubMedCentral
127.
Yamazaki H, Tsuboya T, Katanuma A, Kodama Y, Tauchi S, Dohke M et al. Lack of independent association between fatty pancreas and incidence of type 2 diabetes: 5-year Japanese cohort study. Diabetes Care 2016;39:1677–1683PubMed
128.
Fraulob JC, Ogg-Diamantino R, Fernandes-Santos C, Aguila MB, Mandarim-de-Lacerda CA. A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat diet. J Clin Biochem Nutr 2010;46:212–223PubMedPubMedCentral
129.
130.
Yu TY, Wang CY. Impact of non-alcoholic fatty pancreas disease on glucose metabolism. J Diabetes Investig 2017;8:735–747PubMedPubMedCentral
131.
Harmon JS, Gleason CE, Tanaka Y, Poitout V, Robertson RP. Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes 2001;50:2481–2486PubMed
132.
Poitout V, Amyot J, Semache M, Zarrouki B, Hagman D, Fontes G. Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta 2010;1801:289–298PubMed
133.
Lingvay I, Esser V, Legendre JL, Price AL, Wertz KM, Adams-Huet B et al. Noninvasive quantification of pancreatic fat in humans. J Clin Endocrinol Metab 2009;94:4070–4076PubMedPubMedCentral
134.
Chai J, Liu P, Jin E, Su T, Zhang J, Shi K et al. MRI chemical shift imaging of the fat content of the pancreas and liver of patients with type 2 diabetes mellitus. Exp Ther Med 2016;11:476–480PubMed
135.
Lim S, Bae JH, Chun EJ, Kim H, Kim SY, Kim KM et al. Differences in pancreatic volume, fat content, and fat density measured by multidetector-row computed tomography according to the duration of diabetes. Acta Diabetol 2014;51:739–748PubMed
136.
Kizilgul M, Wilhelm JJ, Beilman GJ, Chinnakotla S, Dunn TB, Pruett TL et al. Effect of intrapancreatic fat on diabetes outcomes after total pancreatectomy with islet autotransplantation. J Diabetes 2018;10:286–295PubMed
137.
Tushuizen ME, Bunck MC, Pouwels PJ, Bontemps S, van Waesberghe JH, Schindhelm RK et al. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care 2007;30:2916–2921PubMed
138.
Wicklow BA, Griffith AT, Dumontet JN, Venugopal N, Ryner LN, McGavock JM. Pancreatic lipid content is not associated with beta cell dysfunction in youth-onset type 2 diabetes. Can J Diabetes 2015;39:398–404PubMed
139.
Di Ciaula A, Portincasa P. Fat, epigenome and pancreatic diseases. Interplay and common pathways from a toxic and obesogenic environment. Eur J Intern Med 2014;25:865–873PubMed
140.
Hori M, Takahashi M, Hiraoka N, Yamaji T, Mutoh M, Ishigamori R et al. Association of pancreatic fatty infiltration with pancreatic ductal adenocarcinoma. Clin Transl Gastroenterol 2014;5:e53PubMedPubMedCentral
141.
142.
Katsiki N, Mikhailidis DP, Wierzbicki AS. Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol 2013;28:458–463PubMed
143.
Katsiki N, Mikhailidis DP. Epicardial fat: a novel marker of subclinical atherosclerosis in clinical practice? Anatol J Cardiol 2017;17:64–65PubMedPubMedCentral
144.
Kul S, Karadeniz A, Dursun I, Sahin S, Faruk Cirakoglu O, Rasit Sayin M et al. Non-alcoholic fatty pancreas disease is associated with increased epicardial adipose tissue and aortic intima-media thickness. Acta Cardiol Sin 2019;35:118–125PubMedPubMedCentral
145.
Kim MK, Chun HJ, Park JH, Yeo DM, Baek KH, Song KH et al. The association between ectopic fat in the pancreas and subclinical atherosclerosis in type 2 diabetes. Diabetes Res Clin Pract 2014;106:590–596PubMed
146.
Matsuda M, Shimomura I. Increased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obes Res Clin Pract 2013;7:e330–e341PubMed
147.
Ickin Gulen M, Guven Bagla A, Yavuz O, Hismiogullari AA. Histopathological changes in rat pancreas and skeletal muscle associated with high fat diet induced insulin resistance. Biotech Histochem 2015;90:495–505PubMed
148.
Kebede M, Favaloro J, Gunton JE, Laybutt DR, Shaw M, Wong N et al. Fructose-1,6-bisphosphatase overexpression in pancreatic beta-cells results in reduced insulin secretion: a new mechanism for fat-induced impairment of beta-cell function. Diabetes 2008;57:1887–1895PubMedPubMedCentral
149.
Matheus VA, Monteiro L, Oliveira RB, Maschio DA, Collares-Buzato CB. Butyrate reduces high-fat diet-induced metabolic alterations, hepatic steatosis and pancreatic beta cell and intestinal barrier dysfunctions in prediabetic mice. Exp Biol Med Maywood 2017;242:1214–1226PubMedPubMedCentral
150.
Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. The Lancet 2018;391:541–551
151.
Taylor R, Al-Mrabeh A, Hollingsworth K, Lean M, Sattar N, Shaw J. Remission of type 2 diabetes with return of insulin secretory function restores normal pancreas morphology.
152.
Honka H, Koffert J, Hannukainen JC, Tuulari JJ, Karlsson HK, Immonen H et al. The effects of bariatric surgery on pancreatic lipid metabolism and blood flow. J Clin Endocrinol Metab 2015;100:2015–2023PubMed
153.
Hui SCN, Wong SKH, Ai Q, Yeung DKW, Ng EKW, Chu WCW. Observed changes in brown, white, hepatic and pancreatic fat after bariatric surgery: evaluation with MRI. Eur Radiol 2019;29:849–856PubMed
154.
Heiskanen MA, Motiani KK, Mari A, Saunavaara V, Eskelinen JJ, Virtanen KA et al. Exercise training decreases pancreatic fat content and improves beta cell function regardless of baseline glucose tolerance: a randomised controlled trial. Diabetologia 2018;61:1817–1828PubMedPubMedCentral
155.
Dutour A, Abdesselam I, Ancel P, Kober F, Mrad G, Darmon P et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab 2016;18:882–891PubMed
156.
Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005;21:1997–2006PubMed
157.
Filippatos TD, Gazi IF, Liberopoulos EN, Athyros VG, Elisaf MS, Tselepis AD et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007;193:428–437PubMed
158.
Filippatos TD, Liberopoulos EN, Kostapanos M, Gazi IF, Papavasiliou EC, Kiortsis DN et al. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab 2008;10:476–483PubMed
159.
Athyros VG, Elisaf MS, Alexandrides T, Achimastos A, Ganotakis E, Bilianou E et al. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology 2012;63:358–366PubMed
160.
Athyros VG, Ganotakis E, Kolovou GD, Nicolaou V, Achimastos A, Bilianou E et al. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 2011;9:647–657PubMed
161.
Rask Larsen J, Dima L, Correll CU, Manu P. The pharmacological management of metabolic syndrome. Expert Rev Clin Pharmacol 2018;11:397–410PubMed
162.
Yamazaki H, Tauchi S, Wang J, Dohke M, Hanawa N, Kodama Y et al. Longitudinal association of fatty pancreas with the incidence of type-2 diabetes in lean individuals: a 6-year computed tomography-based cohort study. J Gastroenterol 2020;55:712–721PubMed
163.
Tirkes T, Jeon CY, Li L, Joon AY, Seltman TA, Sankar M et al. Association of pancreatic steatosis with chronic pancreatitis, obesity, and type 2 diabetes mellitus. Pancreas 2019;48:420–426PubMedPubMedCentral
164.
Wong VW, Wong GL, Yeung DK, Abrigo JM, Kong AP, Chan RS et al. Fatty pancreas, insulin resistance, and beta-cell function: a population study using fat-water magnetic resonance imaging. Am J Gastroenterol 2014;109:589–597PubMed
165.
Ahbab S, Ünsal A, Ataoğlu HE, Can TS, Kayaş D, Savaş Y. Prediabetes and type 2 diabetes are independent risk factors for computed tomography-estimated nonalcoholic fatty pancreas disease. Clin Sao Paulo Braz 2019;74:e1337
166.
Xie J, Xu L, Pan Y, Li P, Liu Y, Pan Y et al. Nonalcoholic fatty pancreas disease is related independently to the severity of acute pancreatitis. Eur J Gastroenterol Hepatol 2019;31:973–978PubMed
167.
Tahtacı M, Algın O, Karakan T, Yürekli ÖT, Alışık M, Köseoğlu H et al. Can pancreatic steatosis affect exocrine functions of pancreas? Turk J Gastroenterol Off J Turk Soc Gastroenterol 2018;29:588–594
168.
Desai V, Patel K, Sheth R, Barlass U, Chan Y-M, Sclamberg J et al. Pancreatic fat infiltration is associated with a higher risk of pancreatic ductal adenocarcinoma. Visc Med 2020;36:220–226PubMedPubMedCentral
169.
Fukuda Y, Yamada D, Eguchi H, Hata T, Iwagami Y, Noda T et al. CT density in the pancreas is a promising imaging predictor for pancreatic ductal adenocarcinoma. Ann Surg Oncol 2017;24:2762–2769PubMed
170.
Rebours V, Gaujoux S, d’Assignies G, Sauvanet A, Ruszniewski P, Lévy P et al. Obesity and fatty pancreatic infiltration are risk factors for pancreatic precancerous lesions (panin). Clin Cancer Res Off J Am Assoc Cancer Res 2015;21:3522–3528
171.
Takahashi M, Hori M, Ishigamori R, Mutoh M, Imai T, Nakagama H. Fatty pancreas: a possible risk factor for pancreatic cancer in animals and humans. Cancer Sci 2018;109:3013–3023PubMedPubMedCentral
172.
Tomita Y, Azuma K, Nonaka Y, Kamada Y, Tomoeda M, Kishida M et al. Pancreatic fatty degeneration and fibrosis as predisposing factors for the development of pancreatic ductal adenocarcinoma. Pancreas 2014;43:1032–1041PubMed
173.
Wu WC, Wang CY. Association between non-alcoholic fatty pancreatic disease (NAFPD) and the metabolic syndrome: case-control retrospective study. Cardiovasc Diabetol 2013;12:77PubMedPubMedCentral
174.
Della Corte C, Mosca A, Majo F, Lucidi V, Panera N, Giglioni E et al. Nonalcoholic fatty pancreas disease and nonalcoholic fatty liver disease: more than ectopic fat. Clin Endocrinol Oxf 2015;83:656–662PubMed
Metadaten
Titel
Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, “Prediabetes,” Diabetes and Atherosclerosis
verfasst von
T. D. Filippatos
K. Alexakis
V. Mavrikaki
D. P. Mikhailidis
Publikationsdatum
19.01.2021
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 1/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-06824-7

Weitere Artikel der Ausgabe 1/2022

Digestive Diseases and Sciences 1/2022 Zur Ausgabe

EDITORIAL

The Question That Doesn’t Seem to Go Away: Cancer Risk of Anti-TNF Therapy

Original Article

Pancreatic Steatosis Is Associated with Both Metabolic Syndrome and Pancreatic Stiffness Detected by Ultrasound Elastography

Original Article

Fungal Dysbiosis in Children with Celiac Disease

Review

New Insights into the Role of Oral Microbiota Dysbiosis in the Pathogenesis of Inflammatory Bowel Disease

Original Article

De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months

Original Article

Acceptability and Adequacy of a Non-endoscopic Cell Collection Device for Diagnosis of Barrett’s Esophagus: Lessons Learned

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Parkinson-Krankheit | Nachrichten

Viel Bewegung in der Parkinsonforschung

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise